IMPEDIMED LIMITED — Capital/Financing Update 2010

Apr 6, 2010

==> picture [110 x 104] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

7 April 2010

ASX / MEDIA RELEASE

IMPEDIMED ANNOUNCES NEW FDA SUBMISSION: A MAJOR MILESTONE IN THE EXPANSION OF AVAILABLE MARKET OPPORTUNITY

ImpediMed Limited announces another major milestone today after lodging an application with the US Food and Drug Administration (FDA) to expand the indications for use of ImpediMed’s L-Dex[®] U400 device.The L-Dex U400 is the first device with FDA clearance for unilateral arm applications applied to breast cancer patients. ImpediMed believes, that if successful, this new claim will allow the Company to target a far broader range of healthcare professionals including general surgeons, oncologists and physical therapists, all of whom could be involved in the much larger market of the prevention of lower limb lymphoedema.

CEO Greg Brown said, “We are very pleased to achieve this milestone. The leg market for lymphoedema represents around 80% of all secondary lymphoedema cases, and of these 60 to 70% are unilateral cases[1] . It has long been suspected that the early identification and treatment of lymphoedema can prevent the progression of the condition in patients with leg involvement. Studies are underway to demonstrate the effectiveness of pre-emptive care in pelvic related cancers and the number of patients who could benefit is significant. The Company is also well positioned to now target coverage by insurers on the new CPT code for arms and legs. “

“All of these factors coming together bode well for the Company to significantly grow its revenues going forward,” Mr. Brown added.

ImpediMed’s Medical Director, Dr. Walton Taylor said, “I would love to use the L- Dex test as a clinical tool to assess the lymphatics in all of my cancer patients. Lymphoedema has historically been a significant issue in Melanoma and some of the pelvic cancers.”

“With this claim, surgeons can now simply clinically assess patients for the earliest signs of lymphoedema and start treatment and education earlier,” Dr. Taylor added.

ImpediMed’s L-Dex devices are the only TGA, FDA, and CE cleared devices that offer simple point of care, standardised and objective metrics to aid in the clinical assessment of lymphoedema. They enable medical professionals to provide preoperative clinical assessments and ongoing monitoring of patients for the early signs of lymphoedema. This allows early, simple, cost effective treatment which can assist in preventing the progression of lymphoedema to irreversible forms, helping to improve the quality of life of patients while easing the substantial financial burden on patients and governments.

1/2

1. Abu-Rustum, N.R., et al., The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol, 2006. 103(2): p. 714-8

ENDS For further information contact:

Greg Brown ImpediMed CEO T: 61-7-3860-3700 Mobile/Cell: +61408281127

==> picture [303 x 83] intentionally omitted <==

L-Dex[®] is a trademark of ImpediMed Limited.

“ L-Dex[® ] values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Preoperative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.